Verano Holdings (VRNO) Income from Non-Controlling Interests (2021 - 2023)
Verano Holdings (VRNO) reported Income from Non-Controlling Interests of -$78000.0 for Q4 2023, down 200.0% quarter-over-quarter from $78000.0 in Q3 2023.
Verano Holdings (VRNO) Income from Non-Controlling Interests (2021 - 2023) Analysis & Trends
Verano Holdings (VRNO) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$78000.0 in Q4 2023.
- Income from Non-Controlling Interests for Q4 2023 came in at -$78000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was -$78000.0 (changed N/A YoY), and the FY2022 annual result was $291000.0, down 88.4% from the prior year.
- Income from Non-Controlling Interests retreated to -$78000.0 in Q4 2023 per VRNO's latest filing, from $78000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $594000.0 in Q4 2021 and troughed at -$78000.0 in Q4 2023.
- A 3-year average of $255666.7 and a median of $194500.0 in 2021 frame the typical range for Income from Non-Controlling Interests.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Verano Holdings | - | - | 98.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -78,000.00 |
| Sep 30, 2023 | 78,000.00 |
| Mar 31, 2022 | 291,000.00 |
| Dec 31, 2021 | 594,000.00 |
| Sep 30, 2021 | 551,000.00 |
| Jun 30, 2021 | 98,000.00 |